• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Breast Cancer and Incident Cardiovascular Events. A Systematic Analysis at the Nationwide Level
CONCLUSIONS: In a large and contemporary analysis of female patients seen in French hospitals, women with history of breast cancer had higher risk of all-cause mortality, new onset heart failure and major bleeding compared to a matched cohort of women without breast cancer. In contrast, they have a reduced risk of cardiovascular mortality, MI, and stroke.PMID:35113450 | DOI:10.1111/eci.13754
Source: Clinical Genitourinary Cancer - February 3, 2022 Category: Cancer & Oncology Authors: Ying X Gue Arnaud Bisson Alexandre Bodin Julien Herbert Gregory Y H Lip Laurent Fauchier Source Type: research

Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study
CONCLUSION: Women with BC had increased incidence of CVD events, CVD-related mortality, and all-cause mortality compared with women without BC, and risks varied according to the history of cancer treatment received. Studies are needed to determine how women who received BC treatment should be cared for to improve cardiovascular outcomes.PMID:35385342 | DOI:10.1200/JCO.21.01736
Source: Clinical Genitourinary Cancer - April 6, 2022 Category: Cancer & Oncology Authors: Heather Greenlee Carlos Iribarren Jamal S Rana Richard Cheng Mai Nguyen-Huynh Eileen Rillamas-Sun Zaixing Shi Cecile A Laurent Valerie S Lee Janise M Roh Margarita Santiago-Torres Hanjie Shen Dawn L Hershman Lawrence H Kushi Romain Neugebauer Marilyn L Kw Source Type: research

Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
CONCLUSION: For patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.PMID:36585562 | DOI:10.1007/s12094-022-03034-z
Source: Clinical Genitourinary Cancer - December 30, 2022 Category: Cancer & Oncology Authors: Orla A Houlihan Georgios Ntentas David J Cutter Patricia Daly Charles Gillham Orla McArdle Frances K Duane Source Type: research